Next-generation therapies for the treatment of cancer
AdvanCell is an Australian clinical stage radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy.
Our groundbreaking technology
Changing the Course of Cancer Treatment
Alpha 212®
Alpha 212® is the product of AdvanCell’s ²¹²Pb generator. It is a quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API) manufactured to international GMP standards.
Read more →
Therapeutic Portfolio
Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.
Read more →
The AdvanCell ²¹²Pb Generator
Our proprietary manufacturing platform capable of delivering a scalable solution to fully automated, GMP compliant manufacture of targeted alpha therapies.
Read more →
